KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Common Equity (2016 - 2025)

Neogenomics (NEO) has disclosed Common Equity for 16 consecutive years, with $836.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 7.29% year-over-year to $836.6 million, compared with a TTM value of $836.6 million through Dec 2025, down 7.29%, and an annual FY2025 reading of $836.6 million, down 7.29% over the prior year.
  • Common Equity was $836.6 million for Q4 2025 at Neogenomics, roughly flat from $838.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $1.1 billion in Q2 2021 and bottomed at $836.6 million in Q4 2025.
  • Average Common Equity over 5 years is $962.7 million, with a median of $944.5 million recorded in 2023.
  • The sharpest move saw Common Equity soared 75.53% in 2021, then fell 10.93% in 2022.
  • Year by year, Common Equity stood at $1.1 billion in 2021, then decreased by 9.95% to $998.0 million in 2022, then dropped by 5.66% to $941.5 million in 2023, then dropped by 4.16% to $902.3 million in 2024, then fell by 7.29% to $836.6 million in 2025.
  • Business Quant data shows Common Equity for NEO at $836.6 million in Q4 2025, $838.3 million in Q3 2025, and $854.0 million in Q2 2025.